Effects of metrifonate on memory impairment and cholinergic dysfunction in rats

European Journal of Pharmacology

Volumn 322, Issue 1, 1997, Pages 11-19

  Itoh, Akio ^a   Nitta, Atsumi ^a,b   Katono, Yuki ^a   Usui, Miho ^a   Naruhashi, Kazumasa ^a   Iida, Ryuichi ^a   Hasegawa, Takaaki ^a   Nabeshima, Toshitaka ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Acetylcholine; Alzheimer's disease; Basal forebrain lesion; Cholinesterase inhibitor; Rat; Scopolamine

Indexed keywords

ACETYLCHOLINE; CHOLINE; CHOLINESTERASE; METRIFONATE; ORGANOPHOSPHORUS COMPOUND;

ANIMAL MODEL; ARTICLE; BRAIN CORTEX; BRAIN INJURY; CHOLINERGIC ACTIVITY; CHOLINESTERASE INHIBITION; CONTROLLED STUDY; FOREBRAIN; LEARNING DISORDER; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ACETYLCHOLINE; AMNESIA; ANIMALS; AUTONOMIC NERVOUS SYSTEM DISEASES; AVOIDANCE LEARNING; BRAIN; CHOLINERGIC ANTAGONISTS; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; LEARNING; MALE; MAZE LEARNING; MEMORY DISORDERS; MICRODIALYSIS; PROSENCEPHALON; RATS; RATS, WISTAR; SCOPOLAMINE; SYMPATHETIC NERVOUS SYSTEM; TRICHLORFON;

EID: 0030931020     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(96)00977-6     Document Type: Article

References (50)

1. Becker, R.E. and E. Giacobini, 1988, Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type: clinical, pharmacological, and therapeutic aspects, Drug Dev. Res. 12, 163.
2. Becker, R.E., J. Colliver, R. Elble, E. Feldman, E. Giacobini, V. Kumar, S. Markwell, P. Morieearty, R. Parks, S.D. Shillcutt, L. Unni, S. Vicari, C. Womack and R.F. Zee, 1990, Effects of metrifonate, a long-acting cholinesterase inhibitor, in Alzheimer disease: report of an open trial, Drug Dev. Res. 19, 425.
3. Bierer, L.M., V. Haroutunian, S. Gabriel, P.J. Knott, L.S. Carlin, D.P. Purohit, D.P. Perl, J. Schmiedeler, P. Kanof and K.L. Davis, 1995, Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits, J. Neurochem. 64, 749.
4. Blokland, A., V. Hinz and B.H. Schmidt, 1996, Effects of metrifonate and tacrine in the spatial Morris task and modified Irwin test: evaluation of the efficacy/safety profile in rats, Drug Dev. Res. 36, 166.
5. Coyle, J.T., D.L. Price and M.R. DeLong, 1983, Alzheimer's disease: cortical cholinergic innervation, Science 219, 1184.
6. Davies, P. and A.J.F. Maloney, 1976, Selective loss of central cholinergic neurons in Alzheimer's disease, Lancet ii, 1403.
7. De Boer, P., B.H.C. Westerink and A.S. Horn, 1990, The effect of acetylcholinesterase inhibition on the release of acetylcholine from the striatum in vivo: interaction with autoreceptor responses, Neurosci. Lett. 116, 357.
8. Dunnett, S.B., I.Q. Whishaw, G.H. Jones and S.T. Bunch, 1987, Behavioral, biochemical and histochemical effects of different neurotoxic amino acids injected into nucleus basalis magnocellularis of rats, Neuroscience 20, 653.
9. Ellman, G.L., K.D. Courtney, Y. Andres Jr. and R.M.A. Featherstone, 1961, A new and rapid colorimetric determination of acetylcholinesterase activity, Biochem. Pharmacol. 7, 88.
10. Flood, J.F., 1985, Effect of acute arecoline, tacrine, and arecoline + tacrine post-training administration on retention in late middle-aged mice, J. Gerontol. Biol. Sci. 43, 54.
11. 3H]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal, J. Neurochem. 47, 1948.
12. Hasegawa, M., H. Kinoshita, M. Amano, T. Hasegawa, T. Kameyama and T. Nabeshima, 1993, MK-801 increases endogenous acetylcholine release in the rat parietal cortex: a study using brain microdialysis, Neurosci. Lett. 150, 53.
13. Hepler, D.J., G.L. Wenk, B.L. Cribbs, D.S. Olton and J.T. Coyle, 1985, Memory impairments following basal forebrain lesions, Brain Res. 346, 8.
14. Hinz, V., S. Grewig and B. Schmidt, 1995, Effects of metrifonate and its hydrolytic degradation product dichlorvos on cholinesterase activity in rat brain, erythrocytes, and plasma after single oral administration, Abstract Book of the 9th International Symposium on Cholinergic Mechanisms, June 7-10, Mainz, No. 77.
15. Holmstedt, B., I. Nordgren, M. Sandoz and A. Sundwall, 1978, Metrifonate. Summary of lexicological and pharmacological information available, Arch. Toxicol. 41, 3.
16. 9 receptors, Eur. J. Pharmacol. 213, 243.
17. Ishii, Y., J. Kojima, N. Ikeda and K. Kawashima, 1994, Effect of NIK-247 on basal concentration of extracellular acetylcholine in the cerebral cortex of conscious, freely moving rats, Jpn. J. Pharmacol. 66, 289.
18. Kawashima, K., T. Hayakawa, Y. Kashima, T. Suzuki, K. Fujimoto and H. Oohara, 1991, Determination of acetylcholine release in the striaturn of anesthetized rats in vivo microdialysis and a radioimmunoassay, J. Neurochem. 57, 882.
19. Kawashima, K., A. Sato, M. Yoshizawa, T. Fujii, K. Fujimoto and T. Suzuki, 1994, Effects of centrally acting cholinesterase inhibitors tetraaminoacridine and E2020 on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats, Naunyn-Schmiedeberg's Arch. Pharmacol. 350, 523.
20. Knapp, S., M.L. Wardlow, K. Albert, D. Waters and L.J. Thai, 1991, Correlation between plasma physostigmine concentration and percentage of acetylcholinesterase inhibition over time after controlled release of physostigmine in volunteer subjects, Drug Metab. Dispos. 19, 400.
21. Kumar, V. and R.E. Becker, 1989, Clinical pharmacology of tetrahydroaminoacridine: a possible therapeutic agent for Alzheimer disease, Int. J. Clin. Pharmacol. Ther. Toxicol. 27, 478.
22. Kwo-On-Yuen, P.F. and L.J. Thai, 1989, Tetrahydroaminoacridine improves the spatial acquisition deficit produced by nucleus basalis lesions in rats, Neurology 39 (Suppl. 1), 388.
23. Mattio, T.G., J.S. Richardson and E. Giacobini, 1985, Acute effects of cholinesterase inhibitors on uptake of choline in the rat iris, Neuropharmacology 24, 325.
24. Messamore, E., N. Ogane and E. Giacobini, 1993, Cholinesterase inhibitor effects on extracellular acetylcholine in rat striatum, Neuropharmacology 32, 291.
25. Mori, F., G. Cuadra and E. Giacobini, 1996, Metrifonate effects on acetylcholine and biogenic amines in rat cortex, Neurochem. Res. 20, 1081.
26. Morris, R., 1984, Development of a water-maze procedure for studying spatial learning in the rats, J. Neurosci. Methods 11, 47.
27. Nabeshima, T., 1993, Behavioral aspects of cholinergic transmission: role of basal forebrain cholinergic system in learning and memory, Prog. Brain Res. 98, 405.
28. Nabeshima, T., E. Maruyama, A. Katoh and T. Kameyama, 1991a, The effect of tacrine (THA) on cycroheximide- and basal forebrain lesion-induced memory deficit in rats, Jpn. J. Pharmacol. 57, 311.
29. Nabeshima, T., S. Ogawa, H. Nishimura, K. Fuji, T. Kameyama and Y. Sasaki, 1991b, Staurosporine facilitates recovery from the basal forebrain-lesion-induced impairment of learning and deficit of cholinergic neuron in rats, J. Pharmacol. Exp. Ther. 257, 562.
30. Nitta, A., K. Hayashi, T. Hasegawa and T. Nabeshima, 1993a, Development of plasticity of brain function with repeated trainings and passage of time after basal forebrain lesions in rats, J. Neural Transm. [GenSect] 93, 37.
31. Nitta, A., K. Murase, Y. Furukawa, K. Hayashi, T. Hasegawa and T. Nabeshima, 1993b, Effects of oral administration of stimulator for nerve growth factor synthesis in basal forebrain-lesioned rats, Eur. J. Pharmacol. 250, 23.
32. Nitta, A., Y. Katono, A. Itoh, T. Hasegawa and T. Nabeshima, 1994, Nicotine reverses scopolamine-induced impairment of performance in passive avoidance task in rats through its action on the dopaminergic neuronal system, Pharmacol. Biochem. Behav. 49, 807.
33. Nordgren, I., M. Bergström, B. Holmstedt and M. Sandoz, 1978, Transformation and action of metrifonate, Arch. Toxicol. 41, 31.
34. Nordgren, I., E. Bengston, B. Holmstedt and B.M. Petterson, 1981, Levels of metrifonate and dichlorvos in plasma and erythrocytes during treatment of schistosomiasis with Bilarcil®, Acta Pharmacol. Toxicol. 49, 79.
35. Paxinos, G. and C. Watson, 1986, The Rat Brain in Stereotaxic Coordinates (Academic Press, New York, NY).
36. Riekkinen Jr., P., J. Sirvio and P. Riekkinen, 1990, The effects of THA on medial septal lesion-induced memory defects, Pharmacol. Biochem. Behav. 36, 237.
37. Riekkinen Jr., P., B. Schmidt, R. Stefanski, J. Kuitunen and M. Riekkinen, 1996, Metrifonate improves spatial navigation and avoidance behavior in scopolamine-treated, medial septum-lesioned and aged rats, Eur. J. Pharmacol. 309, 121.
38. Rossor, M.N., N.J. Garretta, A.L. Johnson, C.Q. Mountjoy, M. Roth and L. Iversen, 1982, A post-mortem study of the cholinergic and GABA systems in senile dementia, Brain 105, 313.
39. Sims, N.R., D.M. Bowen, S.J. Allen, C.C.T. Smith, D. Neary, D.J. Thomas and A.N. Davison, 1983, Presynaptic cholinergic dysfunction in patients with dementia, J. Neurochem. 40, 503.
40. Somani, S.M., S.K. Gupta, A. Khalique and L.K. Unni, 1991, Physiological pharmacokinetic and pharmacodynamic model of physostigmine in the rat, Drug Metab. Dispos. 19, 655.
41. Strada, O., S. Vyas, E.C. Hirsch, M. Ruberg, A. Brice, Y. Agid and F. Javoy-Agid, 1992, Decreased choline acetyltransferase mRNA expression in the nucleus basalis of Meynert in Alzheimer disease: an in situ hybridization study, Proc. Natl. Acad. Sci. USA 89, 9549.
42. Summers, W.K., J.O. Visselman, G.M. Marsh and K. Candelora, 1981, Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients, Biol. Psychiatry 16, 145.
43. Summers, W.K., L.V. Majorski, G.M. Marsh, K. Tachiki and A. Kling, 1986, Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer's type, New Engl. J. Med. 315, 1241.
44. Szerb, J.C. and G.T. Somogyi, 1973, Depression of acetylcholine release from cerebral cortical slices by cholinesterase inhibition and by oxotremorine, Nature New Biol. 241, 121.
45. Unni, L.K., C. Womack, M.E. Hunnant and R.E. Becker, 1994, Pharmacokinetics and pharmacodynamics of metrifonate in humans, Methods Find. Clin. Pharmacol. 16, 285.
46. Van der Staay, F.J., V.C. Hinz and B.H. Schmidt, 1996a, Effects of metrifonate on escape and avoidance learning in young and aged rats, Behav. Pharmacol. 7, 56.
47. Van der Staay, F.J., V.C. Hinz and B.H. Schmidt, 1996b, Effects of metrifonate, its transformation product dichlorvos, and other organophosphorus and reference cholinesterase inhibitors on Morris water escape behavior in young-adult rats, J. Pharmacol. Exp. Ther. 278, 697.
48. Whitehouse, P.J., D.L. Price, R.G. Struble, A.W. Clark, J.T. Coyle and M.R. DeLong, 1982, Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain, Science 215, 1237.
49. Yamada, S., M. Isogai, H. Okudaira and E. Hayashi, 1983, Regional adaptation of muscarinic receptors and choline uptake in brain following repeated administration of diisopropylfluorophosphate and atropine, Brain Res. 268, 315.
50. Yoshida, S. and N. Suzuki, 1993, Antiamnesic and cholinomimetic side-effects of the cholinesterase inhibitors, physostigmine, tacrine and NIK-247 in rats, Eur. J. Pharmacol. 250, 117.